LineaRx was formed last year to commercialize Applied DNA Sciences' technologies for DNA design, manufacture, and chemical modification by large scale PCR.
The system has been evaluated by researchers studying cervical cancer prevention as well as other HPV-related cancers, with positive feedback so far.
In an earnings call, the firm said it sees growth continuing for the BD Max, BD Cor, and Phoenix systems, and in China in general.
At the Henry Ford Health System in Southeast Michigan, bringing on the Roche Cobas Liat for flu testing led to a season of headaches before it started paying off.
Revenues were in line with Wall Street estimates, and revenue growth represented strength across all three of the firm's business segments.
The German firm has developed a PCR technology that rapidly regulates temperature with so-called microcyclers diffused in the master mix solution.
Formerly known as Diassess, the Emeryville, California-based startup will use the funding to finance regulatory clearances and early commercialization.
The Australian molecular diagnostics firm will use the funds to accelerate commercial expansion in North America and global markets.
In US influenza testing, providers see growth in placements within hospital emergency departments, physicians' offices, urgent care centers, and retail clinics.
Filter tips for use with QiaSymphony SP/AS instruments may leak, which could lead to delayed or inaccurate results and cause serious injury or death.
Mass cytometry revenues increased 28 percent to $17.5 million year over year, but microfluidics revenues dropped 16 percent to $10.7 million.
The life science segment saw strong sales in Droplet Digital PCR offset by sales the firm's process media product line.
The firm's molecular diagnostics revenue increased nearly 11 percent with global sales of $170.9 million.
The firm's flow cytometry business contributed about $13.2 million, or 16 percent of the firm's consolidated revenue in the second quarter.
The firm aims to stabilize and protect its existing molecular diagnostics business over the next 12 to 18 months, CEO Jack Kenny said.
The research team said its nanofluidic system increased the proportion of nucleic acid and protein disease biomarkers a billionfold prior to detection.
The deal covers Curetis' Unyvero A50 instrument system and test cartridges, and builds on a separate distribution agreement the company recently signed.
Within the company's diagnostics segment, revenues for molecular assays in particular declined 21 percent year over year.
The firm said that the new funds will enable it to build on the continued commercial expansion of its first product, PredictSure IBD, in the coming months.
The Singapore-based company will debut a system at AACC that performs real-time PCR flu A/B testing in less than 20 minutes for the cost of a lateral flow test.
As the Canadian election season heats up, neither major party has really paid much attention to science, according to Nature News.
BBC News says the uncertainty over Brexit is affecting science funding in the UK.
A new app purports to tell users "how gay" they are by looking at their DNA, but experts tell Futurism that the app is bunk.
In Nature this week: human and great ape cerebral organoids reveal aspects of brain development unique to humans, and more.